CellProthera to Present ProtheraCytes® Clinical Data and Receive a Stem Cell Engineering Abstract Award for Phase I/IIb Results at ISCT 2025 Scientific Annual Meeting in New Orleans

CellProthera CSO Ibon Garitaonandia will present data from recent Phase I/IIb trial for ProtheraCytes at the conference on May 8 Mulhouse, France, April 30, 2025 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, will be presenting two oral abstracts at International Society for Cell & Gene Therapy (ISCT) 2025 New Orleans on May 8 stemming from the recently completed Phase 1/2b EXCELLENT trial for the company’s lead therapy, ProtheraCytes. The trial reported positive safety and efficacy data in patients following severe acute myocardial infarction, demonstrating the potential for ProtheraCytes to repair and regenerate heart tissue in this group. Ibon Garitaonandia, Chief Scientific Officer at CellProthera, will present data on the study’s outcomes, for which CellProthera has been named winner of the Stem Cell Engineering Abstract Award, sponsored by the ISCT Stem Cell Engineering Committee. Garitaonandia will also present data on the validation of the method used for measuring the potency of the therapy, which will be used to release clinical batches in a forthcoming Phase 3 study of ProtheraCytes®, which are expanded autologous CD34+ cells. Details on the two oral abstracts are below: Results of the Phase I/IIb EXCELLENT trial evaluating the safety and efficacy of transendocardial injection of expanded autologous CD34+ cells in patients with recent myocardial infarction: Abstract ID # 32 Session Type: Oral Abstract Session Session Title: HEMATOPOIETIC STEM/PROGENITOR CELLS AND ENGINEERING Session Chair: Maryam Pasdar Session Date/Time: Thursday May 8, 5:00-6:00 pm CT Session Room: 210 Presentation Order: 5 Poster presentation at Poster Networking Reception 1 Wednesday, May 7th 19:00-20:30 CellProthera and Alfresa Holdings sign a Memorandum of Understanding to Advance Phase 3 Development and Future wholesale distribution of ProtheraCytes® in Japan 11 August, 2026 Technology Networks: Could Regenerative Medicine Reverse Damage After a Heart Attack? 02 July, 2026 CellProthera Prepares For Phase 3 Push As Regenerative Cardiology Moves Closer To Clinical Reality 02 June, 2026

The release as fetched from its publisher. cellprothera.com ↗